2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Women’s Health, Biological Processes, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Bleeding and Clotting, Platelet Disorders, Thrombocytopenias, Thrombotic Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Infectious Diseases, Viral, Research, Fundamental Science, Translational Research, Study Population, Animal Model
PAPER

3066 Durable loss of triple-positive apl positivity and multi-lineage immune remodeling following CD3×CD19 bispecific T cell engager therapy

Jason Xu, M.D./Ph.D., Chunli Mei, M.D.2, Xin Guan, M.D.3, Rong Du, M.D.4, Bin Wu, M.D.5, Di Wu, M.D.6, Jingna Li, M.D.7, Xiaoqiang Yan8, May Chien, MD9, Giselle Salmasi, MD10, Matthew Baker11, Vanessa E Kennedy, MD12, Qiubai Li, PhD13
1 Stanford University, Stanford, California, United States
2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,, Wuhan, China
3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,, Wuhan, China
4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,, Wuhan, China
5 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,, Wuhan, China
6 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,, Wuhan, China
7 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,, Wuhan, China
8 iTabMed Ltd., Shanghai, China
9 Stanford University, Stanford, California, United States
10 Stanford University, Stanford, California, United States
11 Stanford University, Stanford, California, United States
12 Stanford University, Stanford, California, United States
13 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,, Wuhan, China

Introduction: Triple-positive antiphospholipid antibody (aPL) status—concurrent lupus anticoagulant (LA), anti-cardiolipin (aCL), and anti-β2-glycoprotein I (anti-β2GPI)—defines the highest-risk antiphospholipid syndrome phenotype, with a 10-year thrombosis incidence of ~37% and frequent recurrence despite anticoagulation. Loss of aPL positivity ("seroconversion") is rare with conventional therapy yet is associated with an ~88% reduction in recurrent thrombosis. CD19 CAR T-cell therapy produces prolonged drug-free remission in autoantibody-mediated disease but requires lymphodepletion and complex autologous manufacturing. CD3×CD19 bispecific T-cell engagers (TCEs) offer an off-the-shelf alternative. We report deep B-cell depletion and durable seroconversion from triple-positive aPL status in a trial participant with refractory SLE treated with a CD3×CD19 TCE, A-319.

Methods: A-319 is a CD3×CD19 TCE evaluated in an investigator-initiated phase I dose-escalation trial in active SLE (NCT06400537). Twelve patients received intravenous A-319 across three cohorts (0.3, 0.6, 1.2 μg/kg): priming at 0.05 μg/kg (Days 1, 3, 5 of Week 1), then cohort-specific dosing three times weekly during Weeks 2–4, with dexamethasone premedication and withdrawal of concurrent immunosuppression. One participant in the highest-dose (1.2 μg/kg) cohort, P11, underwent deep translational profiling because of a 9-year history of persistent triple-positive aPL. She had 26-year SLE (ANA ≥1:3200; anti-Sm and anti-dsDNA positive; baseline SLEDAI-2K 11), Coombs-positive autoimmune hemolytic anemia, livedo racemosa, interstitial lung disease, and inflammatory myositis, without macrovascular thrombosis, glucocorticoid-dependent and refractory to cyclophosphamide, methotrexate, leflunomide, mycophenolate, tacrolimus, plasma exchange, and IVIG. Correlatives through 15 months included aPL (measured by two-step chemiluminescent immunoassay) and SLE serology, complement, immunoglobulins, hemolysis markers, and flow-cytometric lymphocyte subset. Single-cell RNA-sequencing (scRNA-seq) was performed at baseline, Day 28, and Month 3.

Results: Across the 12-patient intravenous cohort, A-319 was well tolerated, with no treatment-related serious adverse events, no grade ≥3 cytokine release syndrome (CRS), and no ICANS; CRS was grade 1 in 11/12 (92%) and hematologic toxicity was minimal. P11 had grade 1 CRS. Peripheral CD19+ B cells became undetectable by Week 3 with sustained depletion through Month 4; naïve-predominant reconstitution began at Month 5. T cells recovered to baseline by Day 28 and expanded thereafter. Transient hypogammaglobulinemia (nadir Month 4) was managed with IVIG. SLEDAI-2K fell from 11 to 4 by Week 4 and to 3 by Month 6, sustained through Month 12, with complete resolution of rash, alopecia, and myositis; SRI-4 was met from Month 3 and LLDAS achieved by Month 9. Strikingly, all aPL seroconverted: aCL (IgA/IgG/IgM) and anti-β2GPI (IgG/IgM) became negative by Month 3 and remained undetectable through Month 15, and LA normalized. Hemoglobin rose from 85–93 g/L to 128 g/L by Month 2, although compensated hemolysis persisted.

scRNA-seq of >300k peripheral immune cells from 12 patients revealed broad multi-lineage immune remodeling following A-319 treatment. At baseline, relative to other trial SLE patients, P11 (n=22k cells) harbored elevated type I interferon gene expression extending beyond lymphocytes to platelets, megakaryocytes, and neutrophils; following A-319, type I interferon signatures were strikingly downregulated across both lymphoid and myeloid compartments. A-319 also restored platelet expression of the GPIb-stabilizing subunit GP1BB and, within erythroid cells, suppressed type I interferon genes with concomitant upregulation of α-globin (HBA1/HBA2) by Month 3. B-cell repertoire analysis showed naïve-predominant reconstitution and no clonal overlap before versus after treatment, in contrast to the clonal expansion observed in the T-cell repertoire.

Conclusions: In a heavily refractory trial participant with triple-positive aPL status, CD3×CD19 TCE therapy produced rapid, profound B-cell depletion associated with prolonged aPL seroconversion, alongside major reductions in SLE disease activity, improvement in immune cytopenias, and suppression of multi-lineage type I interferon programs. These findings support prospective evaluation of aPL seroconversion as a potential endpoint of deep B-cell depletion, warranting further study.

Jason Xu, M.D./Ph.D.: No relevant conflicts of interest to declare.